145 related articles for article (PubMed ID: 33462716)
1. Use of the Twelve-Gene Recurrence Score for Ductal Carcinoma in Situ and Its Influence on Receipt of Adjuvant Radiation and Hormonal Therapy.
Piltin MA; Hoskin TL; Day CN; Shumway DA; Habermann EB; Davis J; Boughey JC
Ann Surg Oncol; 2021 Aug; 28(8):4294-4303. PubMed ID: 33462716
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
5. DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
Rakovitch E; Parpia S; Koch A; Grimard L; Soliman H; Stevens C; Perera F; Kong I; Senthelal S; Anthes M; Wiebe E; Cao J; Goldberg M; Smith S; Spadafora L; Whelan TJ
Breast Cancer Res Treat; 2021 Jul; 188(1):133-139. PubMed ID: 33830392
[TBL] [Abstract][Full Text] [Related]
6. Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.
Gangi A; Topham A; Lee MC; Sun W; Laronga C
South Med J; 2017 Oct; 110(10):649-653. PubMed ID: 28973706
[TBL] [Abstract][Full Text] [Related]
7. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
[TBL] [Abstract][Full Text] [Related]
8. Evaluating patterns of utilization of gene signature panels and impact on treatment patterns in patients with ductal carcinoma in situ of the breast.
Bhutiani N; Vuong B; Egger ME; Eldredge-Hindy H; McMasters KM; Ajkay N
Surgery; 2019 Oct; 166(4):509-514. PubMed ID: 31337506
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
10. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013.
Sagara Y; Freedman RA; Wong SM; Aydogan F; Nguyen A; Barry WT; Golshan M
Breast Cancer Res Treat; 2017 Nov; 166(2):583-592. PubMed ID: 28776282
[TBL] [Abstract][Full Text] [Related]
11. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
[TBL] [Abstract][Full Text] [Related]
12. Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience.
Falco G; Rocco N; Procaccini E; Sommella MG; Bordoni D; Cenini E; Castagnetti F; Sabatino V; Compagna R; Della Corte GA; Accurso A; Amato B; Ferrari G
Int J Surg; 2014; 12 Suppl 2():S47-S49. PubMed ID: 25167849
[TBL] [Abstract][Full Text] [Related]
13. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
Manders JB; Kuerer HM; Smith BD; McCluskey C; Farrar WB; Frazier TG; Li L; Leonard CE; Carter DL; Chawla S; Medeiros LE; Guenther JM; Castellini LE; Buchholz DJ; Mamounas EP; Wapnir IL; Horst KC; Chagpar A; Evans SB; Riker AI; Vali FS; Solin LJ; Jablon L; Recht A; Sharma R; Lu R; Sing AP; Hwang ES; White J;
Ann Surg Oncol; 2017 Mar; 24(3):660-668. PubMed ID: 27704370
[TBL] [Abstract][Full Text] [Related]
15. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.
Fish EB; Chapman JA; Miller NA; Link MA; Fishell E; Wright B; McCready DR; Hiraki GY; Ross TM; Hanna WM; Lickley HL
Ann Surg Oncol; 1998 Dec; 5(8):724-32. PubMed ID: 9869520
[TBL] [Abstract][Full Text] [Related]
16. Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Baehner FL; Miller DP; Fong C; Gu S; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Slodkowska E; Anderson JM; Cherbavaz DB; Shak S; Paszat L
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053207
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the Treatment of Ductal Carcinoma in Situ.
Barrio AV; Van Zee KJ
Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
Halasz SR; O'Keefe T; Wallace AM; Blair SL
Breast Cancer Res Treat; 2021 Apr; 186(2):551-559. PubMed ID: 33180236
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast.
Lalani N; Paszat L; Sutradhar R; Thiruchelvam D; Nofech-Mozes S; Hanna W; Slodkowska E; Done SJ; Miller N; Youngson B; Tuck A; Sengupta S; Elavathil L; Chang MC; Jani PA; Bonin M; Rakovitch E
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1017-24. PubMed ID: 25220719
[TBL] [Abstract][Full Text] [Related]
20. DCIS: Risk Assessment in the Molecular Era.
Knowlton CA; Jimenez RB; Moran MS
Semin Radiat Oncol; 2022 Jul; 32(3):189-197. PubMed ID: 35688517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
